|
Colonic Neoplasms
|
0.350 |
Biomarker
|
group |
LHGDN |
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.
|
17122772 |
2007 |
|
Colonic Neoplasms
|
0.350 |
Biomarker
|
group |
CTD_human |
Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer.
|
21188121 |
2009 |
|
Colonic Neoplasms
|
0.350 |
AlteredExpression
|
group |
LHGDN |
Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.
|
17594720 |
2007 |
|
Colonic Neoplasms
|
0.350 |
AlteredExpression
|
group |
LHGDN |
In primary human colon tumors, all of the epithelial cells also expressed CD133, whereas metastatic colon cancers isolated from liver had distinct CD133+ and CD133- epithelial populations.
|
18497883 |
2008 |
|
Colonic Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
We used immunohistochemistry and quantitative polymerase chain reaction to compare expression of mitochondrial peroxiredoxin 3 (PRX3) in CD133(+)CD44(+) Lgr5(+)cells (CSCs) vs CD133(-)CD44(-)Lgr5(-) colon tumor cells (non-CSCs).
|
26091938 |
2015 |
|
Colonic Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
Although CD133(+) cells are believed to display more CSC-like behavior and be solely responsible for tumor colonization, recent research indicates that CD133(-) cells from metastatic colon tumors not only also possess colonization capacity but also promote the growth of larger tumors in a mouse model than CD133(+) cells, suggesting that an alternative mechanism of metastasis exists.
|
23577199 |
2013 |
|
Colorectal Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
In human specimens, the content of CD133(+)CXCR4(+) cells was higher in liver metastases than in primary colorectal tumors.
|
22871210 |
2012 |
|
Colorectal Neoplasms
|
0.330 |
AlteredExpression
|
group |
LHGDN |
CD133 expression is an independent prognostic marker for low survival in colorectal cancer.
|
18781171 |
2008 |
|
Colorectal Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
|
18829568 |
2008 |
|
Colorectal Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
The results of the present study showed that ABCG2 is expressed in CD133-positive CSCs from human colorectal tumors.
|
27449042 |
2016 |
|
Disorder of eye
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
|
Disorder of eye
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
|
Disorder of eye
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
|
Uterine Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
|
21919130 |
2011 |
|
Diabetes Mellitus
|
0.230 |
Biomarker
|
group |
BEFREE |
These results suggest that quantitative and functional defects of CD34+/AC133+/CD31+/CD45dim cells are associated with diabetes and vascular impairment and that this cell type may be a prognostic indicator of CVD and vascular dysfunction.
|
30321232 |
2018 |
|
Diabetes Mellitus
|
0.230 |
Biomarker
|
group |
RGD |
Fudenine, a C-terminal truncated rat homologue of mouse prominin, is blood glucose-regulated and can up-regulate the expression of GAPDH.
|
11237753 |
2001 |
|
Diabetes Mellitus
|
0.230 |
AlteredExpression
|
group |
BEFREE |
Metformin, one of the biguanides used for the treatment of diabetes, is also known to reduce the risk of cancer development and cancer stem-like cells (CSCs), including the expression of CD133.
|
31042624 |
2019 |
|
Diabetes Mellitus
|
0.230 |
Biomarker
|
group |
BEFREE |
Levels of circulating CD34(+)/VEGFR2(+) and CD133(+)/VEGFR2(+) were significantly higher in the newly diagnosed untreated patients with HL compared to the patients with HL in remission (P = 0.03 and P = 0.005, respectively), in the patients in remission compared to the patients with diabetes (P = 0.011 and P < 0.001, respectively), and in the patients in remission compared to the healthy individuals (P = 0.08 and P = 0.003, respectively).
|
30549248 |
2019 |
|
Hereditary retinal dystrophy
|
0.200 |
Biomarker
|
group |
MGD |
Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration.
|
19228982 |
2009 |
|
Retinal Dystrophies
|
0.110 |
CausalMutation
|
group |
CLINVAR |
Whole Genome Sequencing Increases Molecular Diagnostic Yield Compared with Current Diagnostic Testing for Inherited Retinal Disease.
|
26872967 |
2016 |
|
Retinal Dystrophies
|
0.110 |
GeneticVariation
|
group |
CLINVAR |
Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice.
|
18654668 |
2008 |
|
Retinal Dystrophies
|
0.110 |
CausalMutation
|
group |
CLINVAR |
Next generation sequencing-based molecular diagnosis of retinitis pigmentosa: identification of a novel genotype-phenotype correlation and clinical refinements.
|
24154662 |
2014 |
|
Retinal Dystrophies
|
0.110 |
CausalMutation
|
group |
CLINVAR |
Genotype-phenotype correlation and mutation spectrum in a large cohort of patients with inherited retinal dystrophy revealed by next-generation sequencing.
|
25356976 |
2015 |
|
Retinal Dystrophies
|
0.110 |
CausalMutation
|
group |
CLINVAR |
Next-generation sequencing applied to a large French cone and cone-rod dystrophy cohort: mutation spectrum and new genotype-phenotype correlation.
|
26103963 |
2015 |
|
Retinal Dystrophies
|
0.110 |
CausalMutation
|
group |
CLINVAR |
Cone-rod dystrophy and a frameshift mutation in the PROM1 gene.
|
19718270 |
2009 |